Research Article
Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
Table 1
Demographics and baseline characteristics of patients enrolled into the immunology substudy of GRACE.
| Parameter | | All HIV+ patients () | Virologically suppresseda patients at Wk 48 () |
| Sex, (%) | Men | 19 (59.4) | 13 (68.4) | Women | 13 (40.6) | 6 (31.6) | Race, (%) | Black | 15 (46.9) | 8 (42.1) | Hispanic | 10 (31.3) | 6 (31.6) | White | 7 (21.9) | 5 (26.3) | Mean (SD) viral load, log10 copies/mL | | 4.74 (0.84) | 4.76 (0.82) | Median (range) CD4+ count, cells/mm3 | | 191 (2, 463) | 222 (2, 398) |
|
|
HIV-1 RNA < 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available).
|